Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymoctonan SCHEMBL15532000 | 0.93 | REN (0.52) | RENOPRK1OPRD1CALCRLKEAP1 | |
| Thymoctonan SCHEMBL1230532 | 0.93 | REN (0.52) | RENOPRK1OPRD1CALCRLKEAP1 | |
| SCHEMBL30259604 | 0.90 | REN (0.53) | RENOPRK1OPRD1CALCRLOPRM1 | |
| SCHEMBL2195454 | 0.86 | OPRD1 (0.55) | RENOPRK1OPRD1ACE | |
| SCHEMBL30603858 | 0.86 | CALCRL (0.53) | OPRD1CALCRLKEAP1RAMP1 | |
| SCHEMBL31323239 | 0.86 | CALCRL (0.56) | OPRD1CALCRLKEAP1NMUR2OPRM1 | |
| SCHEMBL29666135 | 0.85 | OPRK1 (0.58) | RENOPRK1OPRD1OPRM1 | |
| SCHEMBL30011888 | 0.84 | OPRM1 (0.55) | RENOPRK1KEAP1NMUR2OPRM1 | |
| SCHEMBL31694408 | 0.84 | F2 (0.58) | OPRK1OPRD1CALCRLOPRM1ACE | |
| SCHEMBL8341607 | 0.82 | OPRD1 (0.55) | OPRK1OPRD1KEAP1NMUR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | REN 2640/4885OPRK1 2737/4885OPRD1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.